# Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

> **NCT04969276** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 306 (actual)

## Conditions studied

- Influenza Immunization
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Quadrivalent Inactivated Influenza High Dose
- **BIOLOGICAL:** COVID-19 mRNA Vaccine (nucleoside modified)

## Key facts

- **NCT ID:** NCT04969276
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-16
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969276, "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04969276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*